NCT00501397已完成1 期
An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- Plasma blood samples for GSK189075 at Day 1 Session 1, Days 5 & 6 Session 3
研究概览
简要总结
The purpose of this research study is to evaluate the effect of several daily doses of ketoconazole (a medication used to treat fungal infections like athlete's foot) on a single dose of GSK189075 (an experimental diabetes drug), and also to evaluate the safety and tolerability of GSK189075 in healthy volunteers. The study will see whether ketoconazole causes GSK189075 to stay in your bloodstream for a longer period of time. It will also examine whether GSK189075 causes any changes in the amount of glucose you have in your urine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are a healthy, non-smoking male or female.
- •Are 18 to 55 years old, inclusive.
- •Have a body weight of > or equal to 110 pounds.
- •Are a female who is unable to have any more children and have a negative pregnancy test.
- •Are willing and able to provide written informed consent before the start of any study-related procedures.
- •Are able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions.
排除标准
- •Smoke or use any tobacco products.
- •Have a known allergic reaction to ketoconazole or study drug.
- •Have a history of regular alcohol consumption greater than 7 drinks per week for females or greater than 14 drinks per week for males.
- •Have a positive drug or alcohol or smoking test at screening or check-in to the clinic.
- •Have participated in another clinical trial within 30 days prior to screening in which you have received an investigational drug.
- •Have donated a pint of blood within 56 days before the first dose of study drug.
- •Have any known or suspected stomach condition (or stomach surgery within the 6 months prior to dosing).
- •Have abnormal liver test results.
- •Have a documented history or diagnosis of cirrhosis.
- •Have positive results for hepatitis C or B, or HIV at screening.
- •Have blood pressure outside of the normal range.
- •Are a male subject who is unwilling to either abstain from sexual activity or unwilling to use birth control during the course of the study.
- •Are using non-prescription drugs, vitamins, herbal or dietary supplements (including St John's Wort) within 7 days before the first dose of study medication,
- •Have any abnormality identified on the screening physical or laboratory examination that the study physician feels would make it inappropriate for you to participate in the study.
结局指标
主要结局
Plasma blood samples for GSK189075 at Day 1 Session 1, Days 5 & 6 Session 3
时间窗: at Day 1 Session 1, Days 5 & 6 Session 3 urine collections for volume
urine collections for volume, glucose, & creatinine at Day 1 Session 1, Days 5 & 6 Session 3.
时间窗: at Day 1 Session 1, Days 5 & 6 Session 3.
次要结局
- Labs:followup(followup)
- Adverse events: all visits(all visits)
- ECG,labs: Screening,Days -1 & 1 Session 1,Day 4 Session 2,Days 5-6 Session 3(Screening,Days -1 & 1 Session 1,Day 4 Session 2,Days 5-6 Session 3)
- Urine: Day 1 Session 1,Days 5-6 Session 3(Day 1 Session 1,Days 5-6 Session 3)
- Vitals: Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup(Screening,Days -1 & 1 Session 1,Days 1-4 Session 2,Days 5-6 Session 3,followup)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
GSK239512 DDI StudyMultiple SclerosisNCT01802931GlaxoSmithKline22
已完成
1 期
Effect of Ketoconazole on Regorafenib (BAY73-4506) PharmacokineticsPharmacokineticsNCT01318265Bayer24
已完成
1 期
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerHematologic MalignancyMalignant LymphomaNCT01324310Celgene15
已完成
1 期
Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid TumorsCancerNCT01000376Eisai Limited12
已完成
1 期
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid TumoursAdvanced Solid TumorsNCT00750425AstraZeneca46